Blog

Amer Zeidan: As 2024 winds down, I contemplate

Amer Zeidan/X

Dec 19, 2024, 21:47

Amer Zeidan: As 2024 winds down, I contemplate

Amer Zeidan, Associate Professor of Medicine (Hematology) at Yale University, shared a post on X:

“As 2024 winds down, I contemplate

I came to USA as an Immigrant in 2004.
First faculty job at Yale University in 2014.
Founded International Consortium for MDS in 2022.
Chief of Heme Malignancies at Yale University in 2024.
Promoted to full professor in 2024.
Helped thousands of patients.
Mentored several rising stars.
Contributed to multiple drug approvals.
360 papers/book chapters.
12,000 citations and H index 56.
Talks/presentations in more then 20 countries
I feel as energized as 2004!”

Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance, shared this post adding:

“Tremendous and highly impactful work globally by superstar Amer Zeidan.”

More posts featuring Amer Zeidan and Petros Grivas.

Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.

Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.